Skip to main content

Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)

Court finds non-infringement by Curio Seeker with respect to over-reaching claim by 10x Genomics

Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a decision in a court case has been made.

The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ: TXG). The UPC has also ordered Curio Bioscience not to offer any product that would violate claim 14 of the ‘391 patent in France, Germany, and Sweden. Accordingly, Curio Bioscience will comply with the order and expects no impact to its commercial business.

This ruling is restricted to the three countries mentioned and does not affect Curio’s activities elsewhere, nor does it impact other Curio products.

The decision arises from 10x’s request for provisional measures and is open to appeal. The main action remains pending.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.79
+0.00 (0.00%)
AAPL  255.78
+0.00 (0.00%)
AMD  207.32
+0.00 (0.00%)
BAC  52.55
+0.00 (0.00%)
GOOG  306.02
+0.00 (0.00%)
META  639.77
+0.00 (0.00%)
MSFT  401.32
+0.00 (0.00%)
NVDA  182.81
+0.00 (0.00%)
ORCL  160.14
+0.00 (0.00%)
TSLA  417.44
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.